← Estrella Immunopharma, Inc. (ESLA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Estrella Immunopharma, Inc. (ESLA)
Biological Products, (No Diagnostic Substances) · market cap $21M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-07-31 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Estrella Immunopharma (ESLA) is a micro-cap clinical-stage biotech with a $33M market cap and a single disclosed asset, EB103, currently in Phase 2 for B-Cell Non-Hodgkin's Lymphoma. The company reported $1.9M in cash as of the latest filing, representing roughly 0.9 months of runway, making near-term dilution or a financing event an acute certainty rather than a risk. A Phase 2 data readout for EB103 is estimated by December 31, 2026.
The catalyst path
- 2027-07-31 (est.)Phase 2 · EB103imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EB103 | Phase 2 | B-Cell Non-Hodgkin's Lymphoma (NHL) |
Price & technical context
3-month
-52.0%
6-month
-55.7%
12-month
-60.5%
52-wk range
$0.43–$3.05
vs 50-day MA
-29.5%
vs 200-day MA
-56.8%
Realized vol
112.1%
Max drawdown
-85.9%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ESLA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.